Parameter | Estimate |
---|---|
Progression in the presence of HPV 16/18, % per year | Â |
   Normal to CIN1[43] | 9.4 |
5.8 | |
3.5 | |
   CIN1 to CIN 2* | 13.6 |
14.0 | |
43.0 | |
   CIN 3 (CIS) to LCC | 4.1 |
10.0 | |
   RCC to DCC [22] | 30.0 |
Progression in the presence of HPV 6/11, % per year | Â |
   Normal to CIN1 [43] | 8.5 |
   Normal to CIN 1 to CIN 2 [43] | 1.9 |
0.0 | |
   CIN 1 to CIN2 * | 0.0 |
   Normal to genital warts [41] | 57 |
Mean HPV infection duration with CIN absent, years | Â |
   HPV 16/18 infection [42] | 1.2 |
   HPV 6/11 infection [42] | 0.7 |
Duration of acquired immunity following HPV infection | 10 years to Lifelong |
Regression of HPV 16/18+ disease, % per year | Â |
   CIN1 to Negative/HPV 16/18 [40]* | 32.9 |
21.0 | |
   CIN 2 to CIN 1 [65] | 13.3 |
   CIN 3 (severe dysplasia) to Negative/HPV 16/18 [49] | 11.0 |
3.0 | |
3.0 | |
Regression of HPV 6/11+ disease, % per year | Â |
   CIN1 to Negative/HPV 6/11* | 55.2 |
87.5 | |
Age and stage-specific cervical cancer mortality, 1997–2002, % per year [69] |  |
   for LCC |  |
15–29 years | 0.7 |
30–39 years | 0.6 |
40–49 years | 0.8 |
50–59 years | 1.9 |
60–69 years | 4.2 |
≥ 70 years | 11.6 |
   for RCC |  |
15–29 years | 13.4 |
30–39 years | 8.9 |
40–49 years | 11.0 |
50–59 years | 10.1 |
60–69 years | 17.6 |
≥ 70 years | 28.6 |
   for DCC |  |
15–29 years | 42.9 |
30–39 years | 41.0 |
40–49 years | 46.7 |
50–59 years | 52.7 |
60–69 years | 54.6 |
≥ 70 years | 70.3 |